

BIOCARTIS








A large, glowing blue DNA double helix structure is the central visual element of the page. It is rendered with a textured, almost crystalline appearance and is set against a dark blue background. The helix curves from the bottom left towards the top right, creating a sense of depth and movement.

HIGH PRECISION DIAGNOSTICS FOR PERSONALIZED MEDICINE

MOLECULAR BIOMARKER RESULTS IN ONLY 3 HOURS! THINK IDYLLA™



The Idylla™ solution is a revolutionary, fully automated, real-time PCR-based molecular testing system designed to offer results in only 3 hours. Accessible on demand and without the need for batching. It makes molecular testing easy, fast and suitable for any lab.

-  Highly sensitive, fully automated biomarker testing
-  Results in only 3 hours
-  On solid and liquid biopsies
-  Limited amount of sample needed
-  24/7 testing on single samples - no need for batching and losing time
-  In-house testing suitable for any lab setting – no need to send samples out
-  Complementary to NGS

MEET IDYLLA™



EGFR	NRAS
ALK	MSI
ROS1	IDH1/2
RET	PIK3CA
METex14	AKT1
NTRK1/2/3	POLE*
BRAF	POLD1*
KRAS	



THINK IDYLLA™
BECAUSE TIME MATTERS

*Under development

NTRK 1/2/3, IDH1/2, PIK3CA, AKT1, POLE and POLD1 are for Research Use Only (RUO), not for use in diagnostic procedures.

GENE EXPRESSION SIGNATURES AND BIOMARKER TESTS AS GUIDANCE FOR CLINICAL DECISION MAKING

IN VITRO DIAGNOSTICS (IVD)



MELANOMA - Merlin™ Assay

Merlin helps identify melanoma patients who may forgo the sentinel lymph node biopsy. The Merlin™ Assay is being commercialized in Europe by Biocartis as a CE-IVD marked manual kit, ahead of the launch of an Idylla™ version of the test which is under development.




RESEARCH ASSAYS (RUO*)



THYROID CANCER - Idylla™ ThyroidPrint® Assay

First-in-class cartridge-based assay for risk stratification of indeterminate thyroid nodules.



BREAST CANCER

APIS PIK3CA qPCR Kit

For efficient and reliable PIK3CA gene mutations detection via quantitative PCR (qPCR).



APIS ESR1 dPCR Kit

For reliable and precise ESR1 mutations detection via digital PCR (dPCR).

APIS ESR1 Mutations Kit

For easy and fast ESR1 mutations detection via quantitative PCR (qPCR).

APIS ESR1 Mutations Controls

For quality control of assays detecting ESR1 mutations.

APIS Breast Cancer Subtyping Kit

For fast classification of breast cancer via RT-qPCR.

CANCER AREA



Lung Cancer



Colorectal Cancer



Melanoma



Blood Cancer



Brain Cancer



Breast Cancer



Thyroid Cancer



Endometrial Cancer*



THINK IDYLLA™
BECAUSE TIME MATTERS

PHARMA PARTNERS



CONTENT PARTNERS




GLOBAL COMPANY
+75 COUNTRIES
BELGIUM BASED

*Under development

Biocartis NV
Generaal De Wittelaan 11B
2800 Mechelen - Belgium
+32 15 632 888

Follow us on   
www.biocartis.com
customerservice@biocartis.com



BIOCARTIS

Idylla™ Platform is CE-marked in Europe in compliance with EU IVD Regulation 2017/746, listed as a class II device in the US under establishment registration 3009972873, and registered in many other countries. Merlin™ Assay is CE-marked in Europe in compliance with the EU IVD directive 98/79/EC, developed by SkylineDx and distributed by Biocartis, and available for sale in Europe. Idylla™ ThyroidPrint is for Research Use Only (RUO), not for use in diagnostic procedures, developed by GeneProDx and distributed by Biocartis. APIS PIK3CA qPCR Kit, APIS ESR1 dPCR Kit, APIS ESR1 Mutations Kit, APIS ESR1 Mutations Controls and APIS Breast Cancer Subtyping Kit are for Research Use Only (RUO), not for use in diagnostic procedures, developed by APIS and distributed by Biocartis, available for sale in selected European countries.

Biocartis and Idylla™ are registered trademarks in Europe, the US and many other countries. The Biocartis and Idylla™ trademarks and logos are used trademarks owned by Biocartis. Idylla™ is available for sale in Europe, the US and many other countries. Please check availability with a Biocartis representative. © February 2025, Biocartis NV. All rights reserved.